Contrasting Arcturus Therapeutics (ARCT) and Its Rivals

Arcturus Therapeutics (NASDAQ:ARCT) is one of 844 publicly-traded companies in the “Biotechnology” industry, but how does it contrast to its rivals? We will compare Arcturus Therapeutics to related businesses based on the strength of its analyst recommendations, institutional ownership, valuation, risk, dividends, profitability and earnings.

Volatility & Risk

Arcturus Therapeutics has a beta of 2.62, suggesting that its stock price is 162% more volatile than the S&P 500. Comparatively, Arcturus Therapeutics’ rivals have a beta of -1.84, suggesting that their average stock price is 284% less volatile than the S&P 500.

Insider and Institutional Ownership

94.5% of Arcturus Therapeutics shares are held by institutional investors. Comparatively, 47.8% of shares of all “Biotechnology” companies are held by institutional investors. 17.8% of Arcturus Therapeutics shares are held by company insiders. Comparatively, 13.1% of shares of all “Biotechnology” companies are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Analyst Recommendations

This is a summary of recent ratings for Arcturus Therapeutics and its rivals, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Arcturus Therapeutics	1	0	6	2	3.00
Arcturus Therapeutics Competitors	9873	15287	45632	1598	2.54

Arcturus Therapeutics currently has a consensus price target of $24.50, suggesting a potential upside of 190.28%. As a group, “Biotechnology” companies have a potential upside of 125.18%. Given Arcturus Therapeutics’ stronger consensus rating and higher possible upside, equities research analysts plainly believe Arcturus Therapeutics is more favorable than its rivals.

Profitability

This table compares Arcturus Therapeutics and its rivals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Arcturus Therapeutics	-285.92%	-46.79%	-36.50%
Arcturus Therapeutics Competitors	-12,323.33%	-195.91%	-30.60%

Valuation & Earnings

This table compares Arcturus Therapeutics and its rivals revenue, earnings per share and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Arcturus Therapeutics	$82.03 million	-$65.78 million	-2.74
Arcturus Therapeutics Competitors	$702.30 million	$9.48 million	-18.96

Arcturus Therapeutics’ rivals have higher revenue and earnings than Arcturus Therapeutics. Arcturus Therapeutics is trading at a higher price-to-earnings ratio than its rivals, indicating that it is currently more expensive than other companies in its industry.

Summary

Arcturus Therapeutics beats its rivals on 10 of the 13 factors compared.

Arcturus Therapeutics Company Profile

Arcturus Therapeutics Holdings Inc. is a biotechnology company founded in 2013 and headquartered in San Diego, California. It develops RNA medicines and vaccines, using its LUNAR lipid-mediated delivery technology and self-amplifying RNA platform to deliver genetic instructions to cells. The company’s pipeline includes investigational treatments for rare diseases, such as ARCT-032 for cystic fibrosis and ARCT-810 for ornithine transcarbamylase deficiency. It has also developed ARCT-154, a self-amplifying mRNA COVID-19 vaccine approved in Japan as Kostaive, and works with partners on the development and commercialization of its products.